Todos os produtos listados são exclusivamente para fins de pesquisa científica — não para consumo humano.
Brasil Peptide Guide
Início / Guias de Pesquisa / Sleep Enhancement Research
Guia de Pesquisa · Atualizado Março 2026

Sleep Enhancement Research

Slow-wave sleep modulation and stress-induced insomnia in EEG models

Apenas para pesquisa: Todas as informações são exclusivamente para fins de pesquisa científica. Estes peptídeos não são aprovados para uso terapêutico humano. Cumpra os requisitos éticos e regulatórios da sua instituição.

O que é esta Categoria?

Sleep quality is increasingly recognised as one of the most powerful levers for health, cognitive performance, and longevity. DSIP (Delta Sleep-Inducing Peptide) was discovered in 1977 when researchers isolated it from rabbit blood during natural sleep and found that injecting it into alert rabbits induced slow-wave (deep) sleep within 30 minutes. Unlike sleeping pills, which work by broadly suppressing brain activity, DSIP specifically promotes delta-wave (slow-wave) sleep — the deepest and most restorative stage — without sedation, respiratory depression, or dependence. Selank contributes to this category through its anxiolytic mechanism: by reducing the hyperarousal (racing thoughts, elevated cortisol, difficulty switching off) that underlies stress-induced insomnia, without the muscle-relaxing or respiratory effects of benzodiazepines.

Para que se Pesquisa

  • Improving deep (slow-wave) sleep duration and quality
  • Reducing sleep onset latency without sedation or "drugged" feeling
  • Stress-related insomnia and hyperarousal at bedtime
  • Studying alternatives to benzodiazepines for sleep research models
  • Circadian rhythm support and normalisation of sleep architecture
  • Combined Selank use for anxiety-driven sleep disruption

Prós e Contras

+DSIP improves sleep architecture (specifically slow-wave sleep) rather than simply increasing total sedation
+No respiratory depression — critical safety advantage over conventional sleep medications
+Selank shows no withdrawal or dependence effects in published rodent studies — unlike benzodiazepines
+Selank is intranasal — no injections required
+Cortisol-reducing effect of Selank may have positive downstream effects beyond sleep
+Non-addictive mechanism — neither compound acts on GABA-A receptors the way benzodiazepines do
DSIP has an extremely short plasma half-life (~30 minutes) — the compound degrades quickly, making dosing protocols challenging
DSIP is practically unavailable from Brasil-accessible vendors as of 2026 — specialised custom synthesis required
Human clinical data for DSIP is very limited and inconsistent across published studies
Selank's sleep benefits are a secondary effect of its anxiolytic action — it is not a direct sleep-inducing agent
Effects of DSIP in human volunteers have shown high inter-individual variability in the few published trials
Without access to sleep EEG monitoring, it is difficult to verify sleep architecture improvement objectively

Cronologia de Efeitos

Baseado em cronogramas de estudos publicados. A extrapolação humana é aproximada — resultados individuais variam.

Início
30–60 minutes (DSIP, animal studies); 30–90 minutes (Selank anxiolytic)
Efeito Máximo
Ongoing with consistent use; Selank effects stable within days
Notas

DSIP-induced delta sleep changes are measurable within the first sleep cycle in animal polysomnography studies. Selank's anxiolytic effects are measurable within 30–60 minutes in animal models and may require 3–7 days of consistent use for stable baseline improvement in self-researchers.

Status Legal no Brasil: DSIP and Selank are unscheduled compounds in Brazil. Neither is a controlled substance or approved medicine in Brazil. Selank is available from Brasil-accessible vendors; DSIP is practically unavailable and would need to be specially ordered. Selank is an approved drug in Russia (Selank® nasal drops).

Visão Geral Científica

Sleep enhancement peptide research focuses primarily on DSIP (Delta Sleep-Inducing Peptide), a nonapeptide originally isolated from rabbit venous blood during natural sleep, and Selank, which has secondary anxiolytic-mediated sleep-improving effects. DSIP was discovered by Schoenenberger and colleagues in 1977 and characterised by its ability to increase the proportion of slow-wave (delta) sleep in multiple species. Research models include polysomnographic recording in freely moving rodents, stress-induced insomnia models, and neonatal/aged animal sleep architecture studies.

Mecanismo de Ação

DSIP interacts with opioid receptors (µ and δ) and modulates GABA-B receptor activity, collectively shifting sleep architecture toward slow-wave dominance. It also suppresses corticotropin-releasing hormone (CRH) release, providing indirect stress-axis modulation that may contribute to sleep onset facilitation. Selank's sleep benefits are mediated through its GABAergic and anxiolytic mechanisms — reducing the hyperarousal that characterises stress-induced insomnia without the respiratory depression associated with benzodiazepines.

Métodos de Administração

Via 1Intravenous / intracerebroventricular (DSIP, animal models)
Preparação

Dissolve lyophilised DSIP in sterile saline immediately before administration. IV bolus or slow infusion over 10 minutes.

Concentração Típica

25–100 µg/mL

Notas

ICV administration is used to demonstrate CNS-direct effects and establish receptor pharmacology. IV is used for systemic pharmacokinetic studies. DSIP crosses the BBB, but BBB penetration rate is dose-dependent.

Via 2Intranasal (Selank)
Preparação

Same as Cognitive Enhancement protocol. 0.1% solution in sterile saline.

Concentração Típica

1 mg/mL

Notas

Selank intranasal administration is preferred for sleep models to replicate the direct CNS route without the stress of injection.

Protocolos de Pesquisa

Polysomnography Model (DSIP)
DSIP
Duração
Acute (single dose) to 5-day chronic
Frequência
Acute: single IV bolus; chronic: once daily IV
Faixa de Dosagem
25–200 µg/kg
Critérios de Avaliação

EEG delta power (0.5–4 Hz band), NREM/REM ratio, sleep latency (time to first NREM epoch), total sleep time

Notas do protocolo: Chronic EEG electrode implantation under stereotaxic surgery is required. Animals must have ≥7-day recovery before baseline recordings.
Stress-Induced Insomnia Model (Selank)
Selank
Duração
7 days
Frequência
Once daily intranasal, 60 min before lights-off
Faixa de Dosagem
100–300 µg per animal
Critérios de Avaliação

Sleep onset latency (EEG), serum corticosterone (evening sample), NREM delta power, open-field locomotion (to control for sedation)

Notas do protocolo: Restraint stress (60 min daily) is used to model chronic psychosocial stress insomnia. Diazepam positive control group is standard.

Estudos Publicados Principais

A delta sleep-inducing peptide (DSIP): the first sleep factor?

1977

Intravenous injection of DSIP extracted from sleeping rabbit blood into alert rabbits produced a significant and reproducible increase in delta wave activity and facilitated transition to NREM sleep within 30 minutes.

Metodologia: Alert rabbit model, IV infusion, EEG recording, n=6, crossover design
PubMed: 409316

Resultados Esperados

Baseado no conjunto de evidências pré-clínicas publicadas. Os resultados podem variar dependendo do modelo, dose e via de administração.

  • Increased delta band power (0.5–4 Hz) in EEG during NREM sleep (DSIP)
  • Reduced sleep onset latency in both acute and stress-model paradigms
  • Increased total NREM sleep time without suppression of REM sleep
  • Reduced serum corticosterone in stress models (Selank)
  • No significant respiratory depression or muscle relaxation (distinguishing from benzodiazepines)

Considerações de Segurança

  • DSIP has a very short half-life (~30 min in plasma) due to rapid enzymatic degradation; formulation stability must be verified before use.
  • ICV administration requires survival surgery with attendant anaesthetic and surgical risks.
  • Selank has shown no withdrawal or dependence effects in published rodent studies; contrast with benzodiazepine positive controls.
  • Not approved for human therapeutic use.

Perguntas Frequentes

Does DSIP induce sleep immediately, like a sedative?

No. DSIP modulates sleep architecture by increasing slow-wave (delta) sleep proportion rather than inducing acute sedation. It reduces sleep latency and shifts sleep pressure toward NREM, but does not produce the sedation or anxiolysis associated with benzodiazepines or barbiturates.

Why is DSIP difficult to source from Brasil-accessible vendors?

DSIP is a relatively low-demand research peptide with a very short plasma half-life that makes in vivo studies technically demanding. Few Brasil-accessible vendors stock it routinely; researchers typically order from specialised synthesis laboratories on a custom basis.

Notas Práticas para Auto-Pesquisadores

Apenas com fins educativos. A autoadministração de compostos de pesquisa acarreta riscos significativos e não é endossado por Brasil Peptide Guide. Consulte um profissional de saúde qualificado antes de considerar qualquer protocolo de auto-pesquisa.

What time of day should I use Selank for sleep benefits?

For sleep applications, self-researchers typically use Selank 60–90 minutes before bedtime. This timing allows the anxiolytic effect to develop before sleep onset, helping reduce the hyperarousal and racing thoughts that prevent falling asleep. Morning use is more common when the goal is daytime anxiety reduction — the compound can be used at either time.

Can DSIP actually be sourced for research?

DSIP is not stocked by most Brasil-accessible vendors due to low demand and synthesis complexity. Researchers requiring DSIP typically contact specialised custom peptide synthesis laboratories directly. The short half-life also means freshly synthesised material is preferable. This category is included because the research literature is extensive, but practical sourcing is significantly harder than for BPC-157 or Selank.

Obtenha Peptídeos para sua Pesquisa

Compare fornecedores de peptídeos acessíveis no Brasil em pureza, testes, envio para o Brasil e preço por mg.